AR033803A1 - Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas - Google Patents
Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinasInfo
- Publication number
- AR033803A1 AR033803A1 ARP010100889A ARP010100889A AR033803A1 AR 033803 A1 AR033803 A1 AR 033803A1 AR P010100889 A ARP010100889 A AR P010100889A AR P010100889 A ARP010100889 A AR P010100889A AR 033803 A1 AR033803 A1 AR 033803A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cr8r8
- optionally substituted
- heterocyclic
- alkenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C07C255/59—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pregnancy & Childbirth (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
Abstract
Compuestos de dianilino escuarano que tienen la fórmula (1), en la que: R se selecciona del grupo que consta de OH, SH y NHSO2Rd; Rd se selecciona del grupo que consta de NR6R7, alquilo, arilalquilo C1-4, arilalquenilo C2-4, heteroarilo, heteroarilalquilo C1-4, heteroarilalquenilo C2-4, heterocíclico y heterocíclico-alquilo C1-4, en el que los anillos arilo, heteroarilo y heterocíclico están todos opcionalmente sustituidos; R6 y R7 son independientemente hidrógeno, o un grupo alquilo C1-4, o R6 y R7 junto con el nitrógeno al que están unidos forman un anillo de 5 a 7 miembros, cuyo anillo contiene opcionalmente un heteroátomo adicional que se selecciona de oxígeno, nitrógeno o azufre, y cuyo anillo puede estar opcionalmente sustituido;R1 se selecciona independientemente del grupo que consta de hidrógeno, halógeno, nitro, ciano, alquilo C1-10 halosustituido, alquilo C1-10, alquenilo C2-10, alcoxi C1-10, alcoxi C1-10 halosustituido, azido, (CR8R8)qS(O)tR4, hidroxi, hidroxialquilo C1-4, arilo, arilalquilo C1-4, ariloxi, arilalquil C1-4-oxi, heteroarilo, heteroarilalquilo, heterocíclico, heterocíclico-alquilo C1-4, heteroarilalquil C1-4-oxi, aril-alquenilo C2-10, heteroaril-alquenilo C2-10, heterocíclico-alquenilo C2-10, (CR8R8)qNR4R5, alquenil C2-10-C(O)NR4R5, (CR8R8)qC(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3H, S(O)3R8, (CR8R8)qC(O)R11, alquenil C2-10-C(O)R11, alquenil C2-10-C(O)OR11(CR8R8)q-C(O)OR12, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)qNHS(O)2R17, (CR8R8)qS(O)2NR4R5, o dos restos R1 juntos pueden formar O-(CH2)s-O- o un anillo insaturado de 5 a 6 miembros; q es 0, o un número entero que tiene un valor de 1 a 10; t es 0, o un número entero que tiene un valor de 1 ó 2; s es un número entero que tiene un valor de 1 a 3; R4 y R5 se seleccionan independientemente del grupo que consta de hidrógeno, alquilo C1-4 opcionalmente sustituido, arilo opcionalmente sustituido, arilalquilo C1-4 opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroaril-alquilo C1-4 opcionalmente sustituido, heterocíclico y heterocíclico-alquilo C1-4, o R4 y R5, junto con el nitrógeno al que están unidos, forman un anillo de 5 a 7 miembros que opcionalmente comprende un heteroátomo adicional seleccionado de oxígeno, nitrógeno y azufre; Y se selecciona independientemente del grupo que consta de hidrógeno, halógeno, nitro, ciano, alquilo C1-10 halosustituido, alquilo C1-10, alquenilo C2-10, alcoxi C1-10, alcoxi C1-10 halosustituido, azido, (CR8R8)qS(O)tR4, hidroxi, hidroxialquilo C1-4, arilo, arilalquilo C1-4, ariloxi, arilalquil C1-4-oxi, heteroarilo, heteroarilalquilo, heteroaril-alquil C1-4-oxi, heterocíclico, heterocíclico-alquilo C1-4, aril-alquenilo C2-10, heteroaril-alquenilo C2-10, heterocíclico-alquenilo C2-10, (CR8R8)qNR4R5, alquenil C2-10-C(O)NR4R5, (CR8R8)qC(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3H, S(O)3R8, (CR8R8)qC(O)R11, alquenil C2-10-C(O)R11, alquenil C2-10-C(O)OR11, C(O)R11, (CR8R8)q-C(O)OR12, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)qNHS(O)2Rd, y (CR8R8)qS(O)2NR4R5, o dos restos Y juntos forman O-(CH2)s-O- o un anillo insaturado de 5 a 6 miembros; n es un número entero que tiene un valor de 1 a 5; m es un número entero que tiene un valor de 1 a 4; R8 es hidrógeno o alquilo C1-4; R10 es alquil C1-10-C(O)2R8; R11 se selecciona del grupo que consta de hidrógeno, alquilo C1-4, arilo opcionalmente sustituido, arilalquilo C1-4 opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroarilalquilo C1-4 opcionalmente sustituido, heterocíclico opcionalmente sustituido o heterocíclico-alquilo C1-4 opcionalmente sustituido; R12 se selecciona de hidrógeno, alquilo C1-10, arilo opcionalmente sustituido y arilalquilo opcionalmente sustituido; y R17 se selecciona del grupo que consta de alquilo C1-4, arilo, arilalquilo, heteroarilo, heteroaril-alquilo C1-4, heterocíclico y heterocíclico-alquilo C1-4, en el que los anillos que contienen arilo, heteroarilo y heterocíclico pueden estar todos ellos opcionalmente sustituidos. Estos compuestos son útiles para el tratamiento de enfermedades mediadas por quimioquinas. También se dan a conocer: composiciones farmacéuticas que los comprenden y el uso de dichos compuestos en la producción de medicamentos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18618300P | 2000-03-01 | 2000-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR033803A1 true AR033803A1 (es) | 2004-01-07 |
Family
ID=22683958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010100889A AR033803A1 (es) | 2000-03-01 | 2001-02-27 | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1261328B1 (es) |
JP (1) | JP2003525242A (es) |
KR (1) | KR20020080460A (es) |
CN (1) | CN1416339A (es) |
AP (1) | AP2002002605A0 (es) |
AR (1) | AR033803A1 (es) |
AT (1) | ATE299698T1 (es) |
AU (1) | AU2001239970A1 (es) |
BG (1) | BG107014A (es) |
BR (1) | BR0108866A (es) |
CA (1) | CA2401659A1 (es) |
CZ (1) | CZ20022932A3 (es) |
DE (1) | DE60112051T2 (es) |
DZ (1) | DZ3309A1 (es) |
EA (1) | EA200200933A1 (es) |
ES (1) | ES2245976T3 (es) |
HU (1) | HUP0300599A3 (es) |
IL (1) | IL151429A0 (es) |
MA (1) | MA25657A1 (es) |
MX (1) | MXPA02008589A (es) |
NO (1) | NO20024133L (es) |
OA (1) | OA12184A (es) |
PE (1) | PE20011190A1 (es) |
PL (1) | PL358540A1 (es) |
SK (1) | SK12352002A3 (es) |
UY (1) | UY26601A1 (es) |
WO (1) | WO2001064208A1 (es) |
ZA (1) | ZA200206988B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL366230A1 (en) * | 2000-05-30 | 2005-01-24 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
US20040132694A1 (en) * | 2001-01-16 | 2004-07-08 | Palovich Michael R. | Il-8 receptor antagonists |
SK9782003A3 (en) * | 2001-02-02 | 2004-01-08 | Schering Corp | 3,4-Di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists |
US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
SI1818325T1 (sl) * | 2001-04-16 | 2010-06-30 | Schering Corp | DI substituirani ciklobuten dioni kot ligandi CXC kemokinskega receptorja |
US6903131B2 (en) | 2001-10-12 | 2005-06-07 | Schering Corporation | 3,4-di-substituted maleimide compounds as CXC chemokine receptor antagonists |
US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
US20040053953A1 (en) * | 2002-03-18 | 2004-03-18 | Schering Corporation | Treatment of chemokine mediated diseases |
MXPA05003867A (es) | 2002-10-09 | 2005-11-23 | Schering Corp | Tiadiazoldioxidos y tiadiazoloxidos como ligandos de receptor cxc-y cc-quimiocina. |
TW200528450A (en) | 2003-12-19 | 2005-09-01 | Schering Corp | Thiadiazoles as cxc-and cc-chemokine receptor ligands |
JP4851943B2 (ja) * | 2003-12-22 | 2012-01-11 | シェーリング コーポレイション | Cxc−ケモカインレセプターリガンドおよびcc−ケモカインレセプターリガンドとしてのイソチアゾールジオキシド |
WO2007002764A2 (en) | 2005-06-29 | 2007-01-04 | Schering Corporation | Di-substituted oxadiazoles as cxc-chemokine receptor ligands |
WO2007005403A1 (en) | 2005-06-29 | 2007-01-11 | Schering Corporation | 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands |
TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Cxcr2抑制劑 |
EP3737366A4 (en) | 2018-01-08 | 2022-07-27 | ChemoCentryx, Inc. | METHOD OF TREATMENT OF GENERALIZED PUSTULOUS PSORIASIS WITH AN ANTAGONIST OF CCR6 OR CXCR2 |
CN112851635B (zh) * | 2019-11-28 | 2022-09-16 | 中国医学科学院药物研究所 | 环状砜类化合物及其制备方法、用途和药物组合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780483A (en) * | 1995-02-17 | 1998-07-14 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
-
2001
- 2001-02-27 AR ARP010100889A patent/AR033803A1/es unknown
- 2001-03-01 ES ES01914603T patent/ES2245976T3/es not_active Expired - Lifetime
- 2001-03-01 JP JP2001563105A patent/JP2003525242A/ja not_active Withdrawn
- 2001-03-01 PL PL01358540A patent/PL358540A1/xx not_active Application Discontinuation
- 2001-03-01 PE PE2001000204A patent/PE20011190A1/es not_active Application Discontinuation
- 2001-03-01 CN CN01805908A patent/CN1416339A/zh active Pending
- 2001-03-01 AT AT01914603T patent/ATE299698T1/de not_active IP Right Cessation
- 2001-03-01 WO PCT/US2001/006564 patent/WO2001064208A1/en not_active Application Discontinuation
- 2001-03-01 SK SK1235-2002A patent/SK12352002A3/sk unknown
- 2001-03-01 BR BR0108866-1A patent/BR0108866A/pt not_active Application Discontinuation
- 2001-03-01 HU HU0300599A patent/HUP0300599A3/hu unknown
- 2001-03-01 EP EP01914603A patent/EP1261328B1/en not_active Expired - Lifetime
- 2001-03-01 DE DE60112051T patent/DE60112051T2/de not_active Expired - Fee Related
- 2001-03-01 AP APAP/P/2002/002605A patent/AP2002002605A0/en unknown
- 2001-03-01 OA OA1200200261A patent/OA12184A/en unknown
- 2001-03-01 CZ CZ20022932A patent/CZ20022932A3/cs unknown
- 2001-03-01 KR KR1020027011448A patent/KR20020080460A/ko not_active Application Discontinuation
- 2001-03-01 DZ DZ013309A patent/DZ3309A1/fr active
- 2001-03-01 AU AU2001239970A patent/AU2001239970A1/en not_active Abandoned
- 2001-03-01 MX MXPA02008589A patent/MXPA02008589A/es unknown
- 2001-03-01 EA EA200200933A patent/EA200200933A1/ru unknown
- 2001-03-01 CA CA002401659A patent/CA2401659A1/en not_active Abandoned
- 2001-03-01 UY UY26601A patent/UY26601A1/es not_active Application Discontinuation
- 2001-03-01 IL IL15142901A patent/IL151429A0/xx unknown
-
2002
- 2002-08-20 BG BG107014A patent/BG107014A/bg unknown
- 2002-08-30 NO NO20024133A patent/NO20024133L/no not_active Application Discontinuation
- 2002-08-30 ZA ZA200206988A patent/ZA200206988B/en unknown
- 2002-09-02 MA MA26799A patent/MA25657A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
BG107014A (bg) | 2003-05-30 |
NO20024133L (no) | 2002-10-31 |
CN1416339A (zh) | 2003-05-07 |
CA2401659A1 (en) | 2001-09-07 |
PL358540A1 (en) | 2004-08-09 |
ZA200206988B (en) | 2003-10-16 |
JP2003525242A (ja) | 2003-08-26 |
CZ20022932A3 (cs) | 2003-05-14 |
EP1261328A4 (en) | 2003-05-28 |
EP1261328A1 (en) | 2002-12-04 |
SK12352002A3 (sk) | 2003-02-04 |
MXPA02008589A (es) | 2003-02-24 |
NO20024133D0 (no) | 2002-08-30 |
OA12184A (en) | 2006-05-09 |
KR20020080460A (ko) | 2002-10-23 |
AP2002002605A0 (en) | 2002-09-30 |
AU2001239970A1 (en) | 2001-09-12 |
DE60112051T2 (de) | 2006-04-27 |
HUP0300599A2 (hu) | 2003-07-28 |
PE20011190A1 (es) | 2002-01-06 |
DZ3309A1 (en) | 2001-09-07 |
HUP0300599A3 (en) | 2003-09-29 |
MA25657A1 (fr) | 2002-12-31 |
UY26601A1 (es) | 2001-08-27 |
BR0108866A (pt) | 2004-02-25 |
DE60112051D1 (de) | 2005-08-25 |
EP1261328B1 (en) | 2005-07-20 |
ATE299698T1 (de) | 2005-08-15 |
EA200200933A1 (ru) | 2003-02-27 |
IL151429A0 (en) | 2003-04-10 |
ES2245976T3 (es) | 2006-02-01 |
WO2001064208A1 (en) | 2001-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR033803A1 (es) | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas | |
AR032398A1 (es) | Compuesto de escuaramida de sulfonamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dicha composicion | |
AR015425A1 (es) | Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion | |
AR038818A1 (es) | Compuesto de piperidina, uso del mismo para preparar un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
AR016817A1 (es) | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento | |
AR038881A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos | |
AR057981A1 (es) | Compuesto de pirroloquinolin -4- ona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios pra su preparacion | |
BR9307580A (pt) | Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano | |
EE03872B1 (et) | Arüülglütsiinamiidi derivaadid, meetod nende valmistamiseks ja neid ühendeid sisaldavad farmatseutilised preparaadid | |
ECSP045498A (es) | "difenilazetidinonas sustituidas en anillo, metodo para su producción, medicamentos que comprenden estos compuestos y su uso" | |
AR030391A1 (es) | Composicion para tratar un estado de enfermedad mediado por quimioquinas y el uso de la misma para la manufactura de un medicamento. | |
AR038421A1 (es) | Compuesto sulfonamida de 1,2,4,5-tetrahidrobenzo (d) azepina, procedimiento para su preparacion, composicion farmaceutica que lo comprende y su uso para preparar esta ultima | |
AR006360A1 (es) | Derivados de 1,2,3,4-tetrahidronaftaleno substituidos, uso de los mismos para la preparacion de medicamentos y procedimiento para su preparacion. | |
AR045793A1 (es) | Compuestos derivados de 3-heterociclil-indol | |
AR037940A1 (es) | Compuestos antivirales de piridoquinoxalina | |
AR039651A1 (es) | Derivados de isoquinolina | |
AR008331A1 (es) | Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen | |
AR037521A1 (es) | Derivados de piperazina que tienen actividad antagonista del sst1, un proceso para su preparacion, composicion farmaceutica y el uso de dichos derivados para la manufactura de un medicamento para el tratamiento de la depresion, ansiedad y padecimientos bipolares y una combinacion | |
CO5190696A1 (es) | Antagonistas de los receptores il-8 | |
BR0100234A (pt) | Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos | |
AR031101A1 (es) | Compuestos de n-(2-hidroxi-3-aminosulfonil-fenil)-n'-fenil guanidina, composiciones farmaceuticasque los comprenden, y uso de dichos compuestos en la manufactura de medicamentos para tratar enfermedades que cursan con mediacion de quimioquinas. | |
DE3883140T2 (de) | Imidazo(2,1-b)benzothiazole und ihre Säureadditionssalze, Verfahren und Zwischenprodukte zu ihrer Herstellung, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zubereitungen. | |
AR031098A1 (es) | Compuestos de hidroxifenil urea sustituidos con sulfonamidas, composiciones farmaceuticas que los comprenden, y uso de los mismos en la fabricacion de medicamentos para tratar una enfermedad mediada por una quimioquina | |
CO5170514A1 (es) | Antagonistas de los receptores de la il-8 nistas del receptor de la il-8 | |
CO4970746A1 (es) | Nuevos compuestos sustituidos de benzoisotiazol para tratamiento de estados mediados por la quimioquina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |